News for BridgeBio Pharma, Inc. (2CL.MU)

PALO ALTO, Calif., March 02, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO), a clinical-stage biopharmaceutical company focused on genetic ...

Molybdenum cofactor deficiency Type A, an ultra-rare, life-threatening genetic disorder that progresses rapidly, results in severe and largely irreversible neurological injury, and has a high... | February 28, 2021

Molybdenum cofactor deficiency (MoCD) Type A, an ultra-rare, life-threatening genetic disorder that progresses rapidly, results in severe and largely

Insider buying can be an encouraging signal for potential investors, especially when markets face uncertainty. Biotech stocks and secondary and i...

Insider buying can be an encouraging signal for potential investors, especially when markets face uncertainty. Biotech stocks and secondary and initial ...

Baron Health Care Fund recently published its fourth-quarter commentary – a copy of which can be downloaded here. During the fourth quarter of 2020,...

Baron Health Care Fund recently published its fourth-quarter commentary – a copy of which can be downloaded here. During the fourth quarter of 2020,...

PALO ALTO, Calif., Feb. 11, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) (the "Company," "we" or "BridgeBio") announced today the launch of ...

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 10) 9 ...

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 9) Abbott ...